CTSO - Company ID 0001175151
The table below shows Cytosorbents Corp's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$1.16M | -$3.47M | -$4.83M | -$3.11M | -$8.12M | -$2.34M |
| Capital expenditure | $11.00K | $2.00K | $45.19K | $509.67K | $710.24K | $428.64K |
| Investing cash flow | -$46.00K | -$47.00K | -$127.02K | -$682.88K | -$847.96K | -$606.34K |
| Dividends paid | - | - |
Cytosorbents Corp reported operating cash flow of -$12.38M for fiscal year 2025. That is up 14.2% from -$14.43M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$6.73M (FY 2016) to -$12.38M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | - | $6.83M | -$571.76K | $684.28K | -$40.36K | $76.55K |